Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Negotiating Prices For Real-World Data Can Lower FDA Submission Costs, Shuren Says

This article was originally published in The Gray Sheet

Executive Summary

A new national evaluation system for devices will provide collective bargaining power to reduce the costs of real-world data to substitute for clinical trials in company submissions.


Related Content

Pilot Of New US Evaluation System Will Include At Least Two Devices
Shuren: FDA Willing to Kick-Start Device Evaluation Program, But Funding Guarantee Needed
Califf Puts Weight Behind 'Sentinel' As Evidence-Generation System Of The Future
Postmarket Surveillance Reform Board Gets Injection Of Device Industry Experience





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts